Effective price: ₹1683
Above 10 years
Our immune system produces antibodies in response to invading exogenous substances such as viruses and bacteria. However, the immune mechanism occasionally misidentifies some of our cells or tissues as hazardous and produces antibodies against them, which are known as autoantibodies. They are frequently found in patients with autoimmune disorders.
U1-nRNP antibodies or anti-ribonucleoprotein antibodies (anti-RNP) are autoantibodies that target the protein ribonucleoprotein (RNP), which is found in the nucleus of each cell in the human body.
Patients with a multitude of systemic rheumatic ailments often have high concentrations of antibodies to ribonucleoprotein. These ailments include Progressive Systemic Sclerosis, Systemic Lupus Erythematosus (SLE), and Mixed Connective Tissue Disease (MCTD), a distinguishable disease entity with intersecting clinical manifestations of Scleroderma, SLE, Rheumatoid Arthritis, and Polymyositis.
Antibodies against RNP are found in around half of lupus erythematosus patients, as well as those with other connective tissue illnesses, such as MCTD. Elevated concentrations of RNP antibodies lacking detectable Sm antibodies or double-stranded DNA antibodies characterise MCTD.
Checking for RNP antibodies is ineffective in patients who do not have antinuclear antibodies. If the individual has a negative antinuclear antibody (ANA), the U1-nRNP antibodies test will be of very low yield.
Anti-RNP antibodies are associated with MCTD but are not diagnostic; an individual may have significant anti-RNP levels but no clinical disease indications. U1-nRNP testing is commonly used to confirm clinically suspected diagnoses and track illness progression. The U1-nRNP antibodies test is used to assess patients with clinical manifestations of a connective tissue illness and a positive antinuclear antibody test.
A positive outcome for RNP antibodies indicates the presence of a connective tissue illness. RNP antibodies, despite their significant association with connective tissue illnesses, are not regarded as a "marker" for any ailment except when discovered in isolation, a positive RNP antibody result is compatible with the identification of MCTD. The level of anti-RNP antibody positivity does not predict the intensity or severity of the disease.
Apollo 24|7 offers a comprehensive U1-nRNP antibodies test. The benefits of an U1-nRNP Antibodies test include:
Why should Apollo be your preferred healthcare partner?
The information mentioned above is meant for educational purposes only and should not be taken as a substitute to your Physician’s advice. It is highly recommended that the customer consults with a qualified healthcare professional to interpret test results